Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California. Show more

Location: 200 Penobscot Drive, Redwood City, CA, 94063, United States | Website: https://www.codexis.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

217.5M

52 Wk Range

$1.90 - $6.08

Previous Close

$2.41

Open

$2.41

Volume

1,473,043

Day Range

$2.29 - $2.43

Enterprise Value

221.1M

Cash

66.33M

Avg Qtr Burn

-15.3M

Insider Ownership

2.29%

Institutional Own.

80.72%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date